pISSN 1976-2283
eISSN 2005-1212

Download original image
Fig. 6. Short-term results for (A) clinical remission, (B) clinical response, and (C) mucosal healing in patients exposed to adalimumab (80/40 mg at weeks 0/2) versus placebo.

CI, confidence interval.

Gut and Liver 2016;10:262~274 https://doi.org/10.5009/gnl15042
© Gut and Liver